CervoMed Inc.

CRVO · Nasdaq · SIC 2834: Pharmaceutical Preparations
421
SEC Filings

Business Summary

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an orally administered small-molecule p38 inhibitor targeting neuroinflammation and synaptic dysfunction. Neflamapimod is in clinical development for Dementia with Lewy Bodies (DLB), nonfluent variant primary progressive aphasia (nfvPPA), Rapid Eye Movement Sleep Behavior Disorder Associated Synucleinopathy (RAS), and ALS. There are no approved therapies for DLB in the US or EU.

Next Earnings

Q2 FY2026 — expected 2026-08-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCRVOdiscussed_in_filing Artificial Intelligence
topic_mentionCRVOdiscussed_in_filing Cybersecurity
topic_mentionCRVOdiscussed_in_filing Trusted Computing
topic_mentionCRVOdiscussed_in_filing Blockchain & Crypto
topic_mentionCRVOdiscussed_in_filing Supply Chain
topic_mentionCRVOdiscussed_in_filing Regulation
topic_mentionCRVOdiscussed_in_filing Healthcare & Bio
topic_mentionCRVOdiscussed_in_filing Platform & Ecosystem
topic_mentionCRVOdiscussed_in_filing Sovereign & Government
topic_mentionCRVOdiscussed_in_filing Artificial Intelligence
topic_mentionCRVOdiscussed_in_filing Cybersecurity
topic_mentionCRVOdiscussed_in_filing Trusted Computing
topic_mentionCRVOdiscussed_in_filing Blockchain & Crypto
topic_mentionCRVOdiscussed_in_filing Supply Chain
topic_mentionCRVOdiscussed_in_filing Regulation
topic_mentionCRVOdiscussed_in_filing Healthcare & Bio
topic_mentionCRVOdiscussed_in_filing Platform & Ecosystem
topic_mentionCRVOdiscussed_in_filing Sovereign & Government
topic_mentionCRVOdiscussed_in_filing Artificial Intelligence
topic_mentionCRVOdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-132025-12-310001437749-26-008259EDGAR90K words
2025-03-172024-12-310001437749-25-007829EDGAR—
2024-03-292023-12-310001437749-24-010064EDGAR—
2023-03-242022-12-310001437749-23-007795EDGAR—
2022-03-182021-12-310001437749-22-006737EDGAR—
2021-03-172020-12-310001437749-21-006236EDGAR—
2020-03-172019-12-310001437749-20-005469EDGAR—
2019-03-192018-12-310001437749-19-005256EDGAR—
2018-04-022017-12-310001437749-18-006050EDGAR—
2017-03-312016-12-310001437749-17-005713EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001437749-25-033879EDGAR25K words
2025-08-082025-06-300001437749-25-025570EDGAR—
2025-05-122025-03-310001437749-25-015966EDGAR—
2024-11-122024-09-300001437749-24-034344EDGAR—
2024-08-092024-06-300001437749-24-025875EDGAR—
2024-05-142024-03-310001437749-24-016615EDGAR—
2023-11-132023-09-300001437749-23-031374EDGAR—
2023-08-082023-06-300001437749-23-022535EDGAR—
2023-05-152023-03-310001437749-23-014359EDGAR—
2022-11-142022-09-300001437749-22-027266EDGAR—
2022-08-122022-06-300001437749-22-020219EDGAR—
2022-05-122022-03-310001437749-22-012143EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001437749-26-009388EDGAR1K words
2026-03-190001437749-26-009081EDGAR—
2026-03-170001437749-26-008611EDGAR—
2026-03-040001437749-26-006911EDGAR—
2026-02-180001437749-26-004555EDGAR—
2026-01-080001437749-26-000883EDGAR—
2025-12-050001437749-25-037025EDGAR—
2025-11-100001437749-25-034095EDGAR—
2025-11-040001437749-25-032869EDGAR—
2025-10-290001437749-25-032184EDGAR—

421 total filings indexed. 389 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

dementia-with-lewy-bodies-(dlb) nonfluent-variant-primary-progressive-aphasia-(nfvppa) rem-sleep-behavior-disorder-associated-synucleinopathy-(ras) amyotrophic-lateral-sclerosis-(als) neurodegenerative-disease-therapeutics

Company Identity

CIK0001053691
TickerCRVO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: abaf5516adfa331e2f897fdd9fc3f549a7a8962c888429d5f89d13b837e1b13a
parent: 0419435116a26d62b75b661018a13757954242c743dccdab60e3e3fa947142a9
content hash: 0dc53acad298ca21cae02572c5b40a9454b2b163237b6adcd93671e4c24acb3d
signed: 2026-04-13T04:44:30.574Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf